Aspo Oyj
Aspo Plc
Managers’ transactions
March 11, 2021 at 14:30
Aspo Plc – Managers’ transactions – Tatu Vehmas
Aspo Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Vehmas Tatu
Position: Member of the Board/Deputy member
Issuer: Aspo Oyj
LEI: 7437000TB0GHDHLPX677
Notification type: INITIAL NOTIFICATION
Reference number: 7437000TB0GHDHLPX677_20210311133604_3
____________________________________________
Transaction date: 2021-03-09
Venue not applicable
Instrument type: SHARE
ISIN: FI0009008072
Nature of the transaction: GIFT, DONATION OR INHERITANCE (RECEIVED)
Transaction details
(1): Volume: 19,938 Unit price: EUR
(2): Volume: 22,852 Unit price: EUR
Aggregated transactions
(2): Volume: 42,790 Volume weighted average price: EUR
Aspo Plc
Arto Meitsalo
CFO
For further information, please contact:
Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com
Aspo is a conglomerate that owns and develops business operations in Northern Europe and growth markets focusing on demanding b-to-b customers. Our strong company brands - ESL Shipping, Leipurin, Telko and Kauko - aim to be the market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these. Together they generate Aspo's goodwill. Aspo's Group structure and business operations are continually developed without any predefined schedules.
Distribution:
Nasdaq Helsinki
www.aspo.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Atico Mining Corporation17.9.2025 22:30:00 CEST | Press release
Atico Signs the Investment Protection Agreement with Government of Ecuador for its La Plata Project
Frontline plc.17.9.2025 22:06:51 CEST | Press release
FRO – Filing of Half Yearly Report
VCI Global Limited17.9.2025 21:00:00 CEST | Press release
VCI Global Initiates Rescission and Cancellation of Shares from QuantGold Transaction, Tightening Capital Structure Following Reverse Split
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom